BELLICUM PHARMACEUTICALS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • March 13th, 2017 • Bellicum Pharmaceuticals, Inc • Pharmaceutical preparations • Texas
This EMPLOYMENT AGREEMENT, dated as of January 25, 2017, is by and between Bellicum Pharmaceuticals, Inc. a Delaware corporation (the “Company”), having an office at 2130 West Holcombe Boulevard, Suite 800, Houston, Texas 77030 and Richard A. Fair (the “Executive”).
January 25, 2017 VIA EMAIL AND HAND DELIVERY Thomas J. FarrellSeparation Agreement • March 13th, 2017 • Bellicum Pharmaceuticals, Inc • Pharmaceutical preparations
This letter sets forth the substance of our agreement (the “Agreement”) regarding your transition and separation from Bellicum Pharmaceuticals, Inc. (the “Company”). This Agreement will become effective only upon the Effective Date specified in Section 12 below.
RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • March 13th, 2017 • Bellicum Pharmaceuticals, Inc • Pharmaceutical preparations
THIS AGREEMENT, made effective the 28th day of October, 2016 (hereinafter the "Effective Date"), is entered into by and between Ospedale Pediatrico Bambino Gesú, having its address at Rome, Piazza S. Onofrio n. 4 - 00165, extra-territorial area in accordance with the Lateran Treaty, in the person of the President of the Board of Directors and Legal Representative, Ms Mariella Enoc (“OPBG”) and Bellicum Pharmaceuticals, Inc., a Delaware corporation, with principal offices located at 2130 W. Holcombe Blvd. Suite 800, Houston, TX 77030 (hereinafter "Bellicum"), each individually a “Party” and collectively the “Parties”, governing research to be conducted at OPBG and at Bellicum.
CO-DEVELOPMENT AND CO-COMMERCIALISATION AGREEMENTCo-Development and Co-Commercialisation Agreement • March 13th, 2017 • Bellicum Pharmaceuticals, Inc • Pharmaceutical preparations • England and Wales
THIS CO-DEVELOPMENT AND CO-COMMERCIALISATION AGREEMENT (“Agreement”) is made and entered into on December 16, 2016 (“Effective Date”) BETWEEN
